Novartis: New SMART Study Data Continues To Support Zolgensma's Clinical Benefits In SMA
4/3 07:51
(RTTNews) - Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), Monday presented new data from the SMART study that continue to support the clinical benefits of Zolgensma (onasemnogene abeparvovec), the only one-time gene therapy for the treatment of spinal musc...